DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Clinical trials for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can stem cell dose boost recovery in tough lymphoma?
Disease control OngoingThis study looks at whether the number of stem cells given during a transplant affects how well the immune system recovers in people with relapsed or refractory diffuse large B-cell lymphoma. About 59 adults who have already tried one chemotherapy and are eligible for a stem cell…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:27 UTC
-
New hope for lymphoma patients: experimental drug combo enters final testing
Disease control OngoingThis study tests whether a new experimental drug (odronextamab) combined with standard chemotherapy works better than the current standard treatment (rituximab plus chemotherapy) for people with diffuse large B-cell lymphoma who have not been treated before. About 904 participant…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New combo therapy shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis study tests whether adding the drug acalabrutinib to a CAR T-cell therapy called liso-cel can help people with aggressive B-cell lymphoma that has come back or not responded to treatment. About 28 adults will receive the combination and be monitored for tumor shrinkage and s…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Patrick C. Johnson, MD • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Triple-Target CAR T-Cells take on Hard-to-Treat lymphomas
Disease control ENROLLING_BY_INVITATIONThis early-phase study tests a new type of immunotherapy called tri-specific CAR T-cells for people with B-cell lymphomas that have come back or not responded to treatment. The therapy is designed to target three different markers on cancer cells to improve effectiveness and redu…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New hope for tough lymphoma: experimental drug shows promise in shrinking tumors
Disease control OngoingThis study tests a new drug called purinostat mesylate in about 74 adults with diffuse large B-cell lymphoma that has returned or not improved after prior therapy. The goal is to see if the drug can shrink tumors and control the cancer safely. Participants receive the drug by inj…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated May 08, 2026 12:01 UTC
-
Elderly lymphoma patients: new tool may predict chemo risks
Knowledge-focused OngoingThis study looks at whether a self-administered geriatric assessment can help predict serious side effects in people aged 60 and older with Non-Hodgkin lymphoma who are starting chemotherapy. The goal is to better understand which patients are at higher risk for hospitalization o…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated May 14, 2026 12:05 UTC